Page last updated: 2024-12-06
1,4-benzenedimethanethiol
1,4-benzenedimethanethiol is a bit of a misnomer, as it suggests a compound with two thiol groups directly attached to the benzene ring. However, the correct structure for this compound, also known as **1,4-bis(mercaptomethyl)benzene**, looks like this:
```
SH
|
S-CH2-Ph-CH2-S
|
SH
```
Here, **Ph** represents the benzene ring.
This molecule is important in research because it offers unique functionalities and can be utilized in various applications:
* **Building Block for Organic Synthesis:** The two thiol groups provide reactive sites for further chemical modifications. This makes 1,4-bis(mercaptomethyl)benzene a versatile building block for synthesizing diverse organic compounds with potential uses in pharmaceuticals, materials science, and other fields.
* **Metal Complexation:** The thiol groups have a strong affinity for various metal ions. This property allows 1,4-bis(mercaptomethyl)benzene to act as a chelating agent, forming stable metal complexes. This is important for applications in areas like:
* **Catalysis:** Metal complexes with 1,4-bis(mercaptomethyl)benzene can act as catalysts in various chemical reactions.
* **Sensors:** The change in color or other properties of the metal complex upon binding to specific ions can be exploited in the development of sensors.
* **Material Science:** 1,4-bis(mercaptomethyl)benzene can be used to create self-assembled monolayers (SAMs) on metal surfaces. These SAMs can modify the surface properties of metals, impacting their wettability, adhesion, and other properties, finding applications in fields like:
* **Corrosion prevention:** SAMs can form a protective layer on metal surfaces, preventing corrosion.
* **Biomaterial development:** SAMs can be modified to create biocompatible surfaces for implants or other biomedical applications.
**Note:** The importance of 1,4-bis(mercaptomethyl)benzene in research is tied to its specific properties and the potential applications it offers in various fields.
Cross-References
ID Source | ID |
PubMed CID | 66043 |
SCHEMBL ID | 127369 |
MeSH ID | M0500989 |
Synonyms (42)
Synonym |
AC-16428 |
NCIOPEN2_000587 |
1,4-benzene dimethanethiol |
p-xylylenedithiol |
1,4-bis(mercaptomethyl)benzene |
105-09-9 |
1,4-benzenedimethanethiol |
1,4-benzenebis(methanethiol) |
p-xylene-.alpha.,.alpha.'-dithiol |
.alpha.,.alpha.'-p-xylenedithiol |
nsc72094 |
nsc-72094 |
1,4-benzenedimethanethiol, 98% |
alpha,alpha'-dimercapto-p-xylene |
b1521 , |
[4-(sulfanylmethyl)phenyl]methanethiol |
A801150 |
nsc 72094 |
k48ubz9imd , |
p-xylene-alpha,alpha'-dithiol |
alpha,alpha'-p-xylenedithiol |
unii-k48ubz9imd |
einecs 203-269-4 |
FT-0606761 |
doi:10.14272/iypnrtqaoxlcqw-uhfffaoysa-n |
10.14272/IYPNRTQAOXLCQW-UHFFFAOYSA-N |
AKOS015897641 |
SCHEMBL127369 |
J-503964 |
DTXSID1059313 |
4-(sulfanylmethyl)benzyl hydrosulfide # |
mfcd00004872 |
AS-58454 |
.alpha.,.alpha.'-dimercapto-p-xylene |
1,4-xylylenedithiol |
1,4-bis(mercaptomethyl)-benzene |
Q63408976 |
3-oxo-3-(3-trifluoromethylphenyl)propionicacidethylester |
1,4-phenylenedimethanethiol |
T70041 |
doi:10.14272/iypnrtqaoxlcqw-uhfffaoysa-n.1 |
10.14272/IYPNRTQAOXLCQW-UHFFFAOYSA-N.1 |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 22.94
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 22.94 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.30 (4.65) | Search Engine Demand Index | 21.17 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |